Next Article in Journal
Monitoring Thermal Ablation via Microwave Tomography: An Ex Vivo Experimental Assessment
Next Article in Special Issue
Metabolomics Biomarkers of Prostate Cancer: A Systematic Review
Previous Article in Journal
A Pilot Study to Non-Invasively Track PIK3CA Mutation in Head and Neck Cancer
Previous Article in Special Issue
Liquid Biopsy Potential Biomarkers in Prostate Cancer
Article Menu
Issue 4 (December) cover image

Export Article

Open AccessReview
Diagnostics 2018, 8(4), 80; https://doi.org/10.3390/diagnostics8040080

Imaging as a Personalized Biomarker for Prostate Cancer Risk Stratification

1
Department of Urology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
2
Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
3
Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
*
Author to whom correspondence should be addressed.
Received: 12 September 2018 / Revised: 13 November 2018 / Accepted: 15 November 2018 / Published: 30 November 2018
(This article belongs to the Special Issue Diagnostic Biomarkers in Prostate Cancer)
Full-Text   |   PDF [278 KB, uploaded 30 November 2018]

Abstract

Biomarkers provide objective data to guide clinicians in disease management. Prostate-specific antigen serves as a biomarker for screening of prostate cancer but has come under scrutiny for detection of clinically indolent disease. Multiple imaging techniques demonstrate promising results for diagnosing, staging, and determining definitive management of prostate cancer. One such modality, multiparametric magnetic resonance imaging (mpMRI), detects more clinically significant disease while missing lower volume and clinically insignificant disease. It also provides valuable information regarding tumor characteristics such as location and extraprostatic extension to guide surgical planning. Information from mpMRI may also help patients avoid unnecessary biopsies in the future. It can also be incorporated into targeted biopsies as well as following patients on active surveillance. Other novel techniques have also been developed to detect metastatic disease with advantages over traditional computer tomography and magnetic resonance imaging, which primarily rely on defined size criteria. These new techniques take advantage of underlying biological changes in prostate cancer tissue to identify metastatic disease. The purpose of this review is to present literature on imaging as a personalized biomarker for prostate cancer risk stratification. View Full-Text
Keywords: magnetic resonance imaging (MRI); Gleason score; cancer staging; active surveillance; radical prostatectomy; radiation therapy magnetic resonance imaging (MRI); Gleason score; cancer staging; active surveillance; radical prostatectomy; radiation therapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Gennaro, K.H.; Porter, K.K.; Gordetsky, J.B.; Galgano, S.J.; Rais-Bahrami, S. Imaging as a Personalized Biomarker for Prostate Cancer Risk Stratification. Diagnostics 2018, 8, 80.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diagnostics EISSN 2075-4418 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top